✅   Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow

Johnson & Johnson (NYSE:JNJ) has always been one of those companies that has a product and service offering so wide and large that JNJ can be considered its own healthcare ETF. Johnson & Johnson operates within the healthcare space with focus on some of the following segments: immunology, infections, neuroscience, and oncology to name a few. In addition, they also operate a segment called MedTech, that provides interventional solutions. With solid financials, a consistent dividend streak, and perseverance within an industry that's been lackluster for some time now, I believe JNJ is more attractive than ever and the price is positioned to gain on the upside.

seekingalpha.com     Apr 12, 2024